azitrainc.com - נכסים נקיים למניה בודדת AZTR

Azitra, Inc. generates revenue through partnerships by creating genetically engineered bacteria for skin therapies. Book value per share data indicates that the parameter reaches 0.12. The brand is valued for its scientific approach to the microbiome and the safety of its anti-itch medications. Additionally, Azitra, Inc. is implementing automated bioreactors to eliminate human error during protein synthesis in laboratories.

The investment attractiveness of Azitra, Inc. (AZTR) depends on the company's ability to maintain material resources amidst geopolitical barriers and disruptions in biomaterial supply chains. The 0.12 metric, calculated as the difference between total equity and liabilities per share, demonstrates the real value of net assets. By analyzing the dynamics of the book value per share, an investor determines the business's fundamental margin of safety and the risk of asset degradation.